NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial. Patients will be allocated in a treatment group (receiving an injection of 5 microg/kg/d of G-CSF during 5 consecutive days) or in a placebo group. Patients will be randomized at admission and will be followed until 3 months after discharge.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
10
Burn Centre of the University Hospital of Liège
Liège, Belgium
IMTR Burn Centre
Loverval, Belgium
Time for healing
Time for complete cutaneous healing, considered as healing of 90% of the body surface area
Time frame: From date of randomization until the date of complete healing, assessed up to 30 days.
Immunohistology: Changes in immunohistologic typing (MAC 387, CD15, CD68, CD45Ro, fact XIIIa)
Changes in immunohistologic typing (MAC 387, CD15, CD68, CD45Ro, fact XIIIa)
Time frame: At admission and at day 5
Biological data: Neutrophilic count
Neutrophilic count
Time frame: Every day during the 14th first days
Biological data: WBC count
WBC count
Time frame: 3 months after discharge
Biological data: WBC formula
WBC formula
Time frame: 3 months after discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.